← Back to Search

Phototherapy

UVA1 Phototherapy for Vitiligo

Phase 2

Waitlist Available

Led By Harvey Lui, MD, FRCPC

Research Sponsored by University of British Columbia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age > 18 years

Localized or generalized vitiligo that involves a non-mucosal or acral site

Timeline

Screening 3 weeks

Treatment Varies

Follow Up assessments at 2, 4, 6, and 8 weeks during treatment then at 4, 8, and 12 weeks post treatment

Awards & highlights

Study Summary

This trial will test whether UVA1 phototherapy is an effective and safe treatment for vitiligo.

Who is the study for?

This trial is for adults over 18 with localized or generalized vitiligo, which isn't on mucosal or acral sites. They should have a patch of at least 25 cm2 with less than 10% repigmentation. It's not for those with severe illness, photosensitivity disorders, recent vitiligo treatments, history of skin cancer, or who are pregnant/breastfeeding.Check my eligibility

What is being tested?

The study tests the effectiveness and safety of UVA1 phototherapy in treating vitiligo. This prospective single-blind randomized clinical trial compares patient outcomes to see how well UVA1 can improve the condition compared to other treatments.See study design

What are the potential side effects?

While specific side effects aren't listed here, UVA1 therapy may cause skin irritation or increase sensitivity to sunlight. Long-term exposure could potentially raise risks for skin aging or cancer; however, these risks need further clarification within this context.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am older than 18 years.

Select...

I have vitiligo on areas of my skin that are not mucous membranes or on my hands and feet.

Select...

I have a skin area of at least 25 cm2 with less than 10% color return.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ assessments at 2, 4, 6, and 8 weeks during treatment then at 4, 8, and 12 weeks post treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~assessments at 2, 4, 6, and 8 weeks during treatment then at 4, 8, and 12 weeks post treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and assessments at 2, 4, 6, and 8 weeks during treatment then at 4, 8, and 12 weeks post treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in the modified VASI score compared to baseline.

Secondary outcome measures

Assessment of side effects in each half including erythema, pruritus, and polymorphous light eruption

Trial Design

2Treatment groups

Active Control

Group I: No treatment (covered)Active Control1 Intervention

Group II: UVA1Active Control1 Intervention

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor

1,413 Previous Clinical Trials

2,466,945 Total Patients Enrolled

4 Trials studying Vitiligo

109 Patients Enrolled for Vitiligo

Harvey Lui, MD, FRCPCPrincipal InvestigatorUniversity of British Columbia

3 Previous Clinical Trials

64 Total Patients Enrolled

3 Trials studying Vitiligo

64 Patients Enrolled for Vitiligo

Media Library

UVA1 (Phototherapy) Clinical Trial Eligibility Overview. Trial Name: NCT01787695 — Phase 2

UVA1 (Phototherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01787695 — Phase 2

Vitiligo Research Study Groups: No treatment (covered), UVA1

Vitiligo Clinical Trial 2023: UVA1 Highlights & Side Effects. Trial Name: NCT01787695 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any patients needed to complete this trial?

"Unfortunately, this study is no longer recruiting patients, as mentioned on clinicaltrials.gov. The listing was first posted on February 1st, 2013 and the most recent update was June 30th, 2015. There are other 41 ongoing trials that are currently accepting patients."

Answered by AI